Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1986 1
1988 1
1991 1
1992 4
1993 4
1994 1
1995 5
1996 8
1997 8
1998 6
1999 5
2000 5
2001 5
2002 7
2003 11
2004 12
2005 9
2006 11
2007 11
2008 6
2009 10
2010 10
2011 10
2012 3
2013 10
2014 13
2015 11
2016 19
2017 15
2018 13
2019 25
2020 25
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

265 results
Results by year
Filters applied: . Clear all
Page 1
Glucagon-like peptide 1 (GLP-1).
Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Müller TD, et al. Among authors: nauck ma. Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. Mol Metab. 2019. PMID: 31767182 Free PMC article. Review.
Therapy of Type 2 Diabetes.
Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein H, Müller-Wieland D, Nauck MA, Reuter HM, Siegel E. Landgraf R, et al. Among authors: nauck ma. Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S73-S92. doi: 10.1055/a-1018-9106. Epub 2019 Dec 20. Exp Clin Endocrinol Diabetes. 2019. PMID: 31860927 Free article. Review. No abstract available.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. Among authors: nauck ma. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Frias JP, et al. Among authors: nauck ma. Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293770 Clinical Trial.
265 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page